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Objectives: Recent research in vascular surgery has focused on development of infection-resistant prosthetic grafts. This
article describes the results of a multicenter study to evaluate safety, patency, and infection rates after implantation of the
InterGard Silver bifurcated polyester graft coated with collagen and silver.
Methods: Between October 2000 and February 2002, 289 consecutive patients were implanted with a collagen and silver
acetate-coated polyester bifurcated graft at 16 French vascular surgery centers. Mean patient age was 65.3  10.9 years.
The indication for prosthetic bypass was aortic aneurysm in 160 patients (55.4%) and symptomatic aortoiliac occlusive
disease in 129 (44.6%). All but four patients received prophylactic antibiotic therapy. Patency was assessed at 30 days, 1
year, 2 years, and 3 years, primarily by duplex scan.
Results: Two patients (0.7%) died during the first 30 days. Median duration of hospitalization was 11 days. The
Kaplan-Meier survival rate at 3 years was 85.7%  4.1%. Primary and secondary patency rates at 3 years were 94.9% 
2.6% and 97.5%  1.8%. Thrombectomy was performed successfully in seven patients, and a major amputation was
required in two patients with patent grafts. Postoperative complications, including 39 nosocomial infections, were
observed in 107 patients (37.0%). Eleven patients presented with 12 wound infections that were classified Szilagyi grade
I in eight cases, grade II in two cases, and grade III with graft infection in two cases (0.7%). Among the 149 patients
undergoing aortofemoral bypass, eight (5.4%) presented with wound infection, including two graft infections (1.3%).
Among the 140 patients undergoing aortoiliac bypass, only three patients (2.1%) presented wound infection and none
with graft infection (P  .15). Three (16.7%) of 18 patients who had undergone previous femoral revascularization and
eight (3%) of 271 patients without previous femoral revascularization presented with wound infection. This difference
was statistically significant (P  .03), with a relative risk of 5.6 (95% confidence interval [CI], 1.6 to 19.5). Five (11.9%)
of 42 diabetic patients and six (2.4%) of 247 nondiabetic patients presented with wound infection. This difference was
also statistically significant (P  .01), with a relative risk of 3.4 (95% CI, 1.7 to 6.9). Lymphorrhea or lymphocele
developed in the groin of 25 patients (8.6%) with negative culture.
Conclusion: This multicenter prospective study shows that the InterGard Silver graft is safe with no side effects. The
primary patency rate was excellent, and the graft infection rate was low, despite a high incidence of nosocomial infections.
(J Vasc Surg 2006;44:339-46.)Aortic graft infection is a rare but life-threatening com-
plication, occurring in 1.5% to 6.0% of patients despite
antibiotic prophylaxis.1-4 It is associated with a mortality
rate of 20% to 75% and limb loss of 20% to 75%, depending
on the type and location of the bypass.1-4 A prosthetic graft
with a collagen and silver acetate coating has recently been
proposed to reduce the risk of prosthetic graft infection.
The antimicrobial properties of silver are well documented5-7
and have been used to enhance the infection resistance of a
number of medical devices.
Statistical demonstration of the efficacy of this strategy
is difficult in the clinical setting owing to the low incidence
of graft infection. Because of this difficulty, not even the
commonly accepted studies on antibiotic prophylaxis in
vascular surgery have reached statistical significance regard-
From Vascular Surgery Department, Jean-Bernard Hospital, University of
Poitiers. Study participants and their affiliations are listed at the end of the
article.
This study was funded by InterVascular, Inc.
Competition of interest: Jean-Baptiste Ricco, MD, PhD, as main investiga-
tor of the study, has received fees for consulting from InterVascular, Inc.
Reprint requests: Jean-Baptiste Ricco, MD, PhD, Vascular Surgery Depart-
ment, Jean-Bernard Hospital, University of Poitiers, 86000 Poitiers,
France (e-mail: jb-ricco@wanadoo.fr).
0741-5214/$32.00
Copyright © 2006 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2006.03.046ing prevention of graft infection.1-4 The purpose of this
prospective study was to evaluate safety, patency, and infec-
tion rate of a bifurcated aortic polyester graft coated with
collagen and silver in a large series of consecutive patients.
We also present the features and mode of action of this
novel graft and the results of the 3-year follow-up of these
patients.
MATERIAL AND METHODS
Silver graft concept. The InterGard Silver (InterVas-
cular, La Ciotat, France) is the first CE-approved graft
designed to reduce the risk of graft infections. Silver is
located in the collagen layer of the graft (Fig 1, A) and in
the fabric of the graft itself (Fig 1, B), providing a substan-
tial release immediately after implantation followed by a
sustained release for up to 30 days.
Unlike antibiotics, silver has not been reported to in-
crease bacterial resistance11,12 because of its mode of ac-
tion. In its ionic (Ag) state, silver acetate exhibits bacteri-
cidal effectiveness against all bacteria.8 The antimicrobial
action of silver ions depends on several mechanisms. Silver
ions penetrate the bacterial cell wall and bind to the phos-
pholipid layer of the cytoplasmic membrane (Fig 2, A). The
ions cause the cell membrane to detach from the cell wall,
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collapse of the first line of defense of the bacteria.9,10
Another antimicrobial effect of silver ions consists of
binding to transcribing DNA (Fig 2, B) at key locations
along the helix.11 This binding disrupts DNA replication
and prevents further cell division.7,11,12 Silver ions also act
by impairing the ability of ribosomes to transcribe messen-
ger RNA into the vital proteins required by the cell to
function (Fig 2, C).
Thiol groups attract the positively charged silver
Fig 1. Microscopic section of InterGard Silver graft (220) col-
ored with Fast Green 1%. Silver distribution is seen both in
collagen layer (A) and in graft fabric (B).
Fig 2. Mechanisms of action of the silver ions on bacteria. A,
Silver ions penetrate the bacterial cell wall and bind to the phos-
pholipid layer of the cytoplasmic membrane. The ions cause the
cell membrane to detach from the cell wall, thus disrupting wall
permeability and causing a gradual collapse of the first line of
defense of the bacteria. B, Silver ions bind with the bacterial
DNAm disrupting DNA replication and interfering with cell divi-
sion. C, Silver ions impair the ability of ribosomes to transcribe
mRNA, and prevent the protein from achieving a proper quater-
nary structure by binding to thiol groups in the proteins.D, Silver
ions bind to the sulfhydryl group of the cytochrome b, shut down
energy production, and eventually stop the cellular respiration.ions,11-12 resulting in the enzyme becoming denatured,unraveling, and thereby losing its ability to function within
the bacteria.11-13 In another mechanism, silver ions hamper
cellular respiration by halting adenosine triphosphate syn-
thesis (Fig 2, D). Consequently, bacteria can no longer
survive with both their structure and function under siege
by the silver ions, and lysis occurs.11
Clinical study. From October 2000 to February
2002, the InterGard Silver bifurcated graft was implanted
in 289 consecutive patients, 268 men (92.7%) and 21
women (7.3%), at 16 French vascular centers. Mean patient
age was 65.3 10.9 years. Patients who required emergent
treatment were excluded. The indication for treatment was
abdominal aortic aneurysm (AAA) in 160 patients (55.4%),
including 31 presenting associated iliac stenosis (Table I),
and aortobiiliac occlusion or stenosis in 129 (44.6%).
Symptoms included claudication in 134 (46.4%), critical
ischemia in 35 (12.1%), and subacute ischemia in five
(1.7%) patients. AAAs were asymptomatic in 103 patients.
For patients presenting with claudication, walking dis-
tance was 100 meters in 81 (60.4%). In the 35 patients
with critical ischemia, 25 (60%) had rest pain, and 14
(40.0%) had an ischemic ulcer or a gangrenous toe. Three
of these patients were receiving preoperative antibiotics.
Risk factors are listed in Table II. In addition, 49
patients (17.0%) had undergone previous revascularization,
including iliac stenting in 9, iliofemoral bypass in 5, aortic
Table I. Arterial lesions treated in this series of 289
consecutive patients.
Lesions Patients Percentage
Aortoiliac occlusive disease 129 44.6
Aortoiliac aneurysm 129 44.6
AAA and iliac occlusive disease 31 10.8
AAA, Abdominal aortic aneurysm.
Table II. Main risk factors in this series of 289 patients
treated for aortoiliac aneurysm or aortoiliac occlusive
disease by implantation of bifurcated silver grafts
Risk factors Patients* Percentage
Systemic
Smoking 224 77.5
Hypertension 165 57.1
Hyperlipidemia 147 50.9
Coronary artery disease 85 29.4
Cardiac insufficiency 12 4.2
Diabetes type I and II 42 14.5
Obesity 34 11.8
Renal insufficiency 22 7.6
Stroke 19 6.6
Local
Previous aortic bypass 4 1.4
*77 patients (26.6%) had only one risk factor, 88 patients (30.4%) had two
risk factors, and 109 patients (37.7%) had three or more risk factors. Only 15
patients (5.2%) had no risk factor.bypass in 4, and lower limb bypass in 8.
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general anesthesia. Bypass was aortobifemoral in 143 cases
(49.5%), aortobiiliac in 140 (48.4%), and bifurcated aor-
toiliofemoral in 4 (1.4%). In the remaining two patients
presenting with AAAs associated with iliac stenosis, the
procedure consisted of bifurcated aortobifemoral grafting
with sequential anastomosis to the internal iliac artery. All
proximal aortic anastomoses were infrarenal with end-to-
end configuration in 191 cases (66.1%) and end-to-side
configuration in 98 (33.9%). Most distal anastomoses (Ta-
ble III) were performed on the common or external iliac
artery (n  284) or common femoral artery (n  237).
During the same procedure, 84 patients (29%) under-
went associated vascular repair, including inferior mesen-
teric artery reimplantation in 33 cases, aortorenal bypass in
9, internal iliac revascularization in 12, peripheral angio-
plasty in 3, and femoropopliteal or tibial bypass in 9.
Antibiotic and antithrombotic drugs. Prophylactic
antibiotic therapy was used in all but four patients (98.6%).
Antibiotics used for prophylaxis were cefamandole in 96
patients (33.2%), cefazolin in 106 (36.7%), cefuroxime in
55 (19.0%), ciprofloxacin in 11 (3.8%), and a combination
of several antibiotics in 16 (5.5%). Vancomycin was used in
one patient with a suspected allergy to cephalosporins. At
the time of discharge, 67 patients (23.2%) were still receiv-
ing some type of antibiotic therapy, mainly for respiratory
and genitourinary tract infections.
Antithrombotic therapy was used in 273 patients
(94.5%). The drugs used for antithrombotic therapy were
anti-platelet agents in 213 patients (73.7%), antivitamin K
in 22 (7.6%), and low molecular weight heparin in 78
(27.0%).
Methodology. Patients from each center were entered
in consecutive order. Data were collected on a standardized
case report form and entered on SPSS (SPSS France SA,
Paris, France). All centers were regularly monitored to
ensure data quality. The primary end point was graft pa-
tency. Secondary end points were patient survival and im-
mediate and long-term complications.
Patency was assessed before discharge from the hospi-
tal, at 1month after surgery, and yearly thereafter by duplex
Table III. Location of distal anastomosis in this series of
patients treated for aneurysmal or occlusive aortoiliac
disease by implantation of 289 bifurcated silver grafts
Location of distal anastomosis Anastomosis (N) Percentage
Common or external iliac artery 284 49.1
Common femoral artery* 237 41.0
Deep femoral artery alone 51 8.8
Superficial femoral artery† 6 1.1
*The graft limb to the common femoral artery (n  237) was also anasto-
mosed with a bifurcated graft to the deep femoral artery in 23 cases and to
the superficial femoral artery in 31 cases.
†The graft limb was anastomosed both on the deep and superficial femoral
arteries in four cases. In one patient, both graft limbs were anastomosed only
on the superficial femoral artery.scan, computed tomography scan, magnetic resonance im-aging, or angiography. Complications were identified and
defined in the protocol and case report form before the
study was begun. All participating investigators agreed to
follow the study protocol, and all complications were sys-
tematically reported. In addition, uniformity in complica-
tions reporting was verified during on-site monitoring visits
by comparing complications recorded in source data with
those in the case report form. To ensure full assessment of
recognized graft-related problems, all postoperative com-
plications were recorded, such as stenosis, dilatation, and
anastomotic abnormalities. Wound infection was classified
according to Szilagyi.14 Graft patency and survival rates
were calculated using the Kaplan-Meier method with 95 %
confidence interval. Basic statistics were done using 2
analysis or Fisher exact test, when applicable. Survival data
were compared using the log-rank test.
RESULTS
Survival. Two patients (0.7%) died during the first 30
days, one from colon and pelvic ischemia and one from
cardiac and liver failure. Median hospital stay was 11 days.
The mean length of follow-up for all patients was 55  10
months (25% percentile, 35 months; 75% percentile, 40
months). Eight patients (2.8%) were lost to follow-up.
During follow-up, 45 patients (15.6%) died, mainly from
cancer (n 17) and complications of atheromatous disease
unrelated to the graft (n  16).
The cumulative survival rates at 1, 2, and 3 years were
95.8  2.3%, 90.2  3.5%, and 85.7  4.1%, respectively
(Fig 3). There was no difference in the survival of patients
treated for occlusive vs aneurysmal disease (P  .41).
Patency. One graft occlusion (0.35 %) involving only
one limb occurred30 days after surgery. Primary patency
rates at 1, 2, and 3 years were 96.8% 2.2%, 95.7% 2.4%,
and 94.9%  2.6%, respectively (Fig 4). Fifteen graft occlu-
sions occurred during follow-up. Seven were successfully
Fig 3. Survival of patients enrolled in the study. Number of
patients at risk is indicated. Survival at 1, 2, and 3 years was 95.8%
 2.3%, 90.2%  3.5%, and 85.7%  4.1% respectively. Dotted
lines show 95 % confidence intervals.treated by surgical thrombectomy, six required another
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occurred in the 129 patients treated for occlusive disease
compared with three in the 160 patients with aneurysmal
disease. The difference between these two groups was
statistically significant (P .02), with a relative risk of 0.53
(95% CI, 0.40 to 0.71). Overall patency in grafts with a
limb diameter of 7 mm (88%) vs grafts with a limb
diameter of8mm (96%), was not significantly lower (P
.08), with a relative risk of 0.42 (95% CI, 0.19 to 0.90).
Limb diameter was not reported in one patient with an
occluded graft. Primary patency was not significantly lower
in patients with risk factors including smoking and diabetes
(P  .39).
Secondary patency at 3 years was 97.5%  1.8% (Fig 5).
Two of the seven patients who had been successfully treated
for graft occlusion presented new occlusions that were
Fig 4. Primary patency of silver polyester bifurcated grafts. Num-
ber of patients at risk is indicated. Primary patency at 1, 2, and 3
years was 96.8%  2.2%, 95.7%  2.4%, and 94.9%  2.6%
respectively. The 95% confidence interval is shown on the figure.
Fig 5. Secondary patency of silver polyester bifurcated grafts.
Number of patients at risk is indicated. Secondary patency was
97.5% 1.8% at 3 years. The 95% confidence interval is shown on
the figure.again successfully treated by surgical thrombectomy.Majoramputation was required despite graft patency in two pa-
tients with inoperable distal occlusive arterial disease.
Intraprocedural complications. Intraprocedural com-
plications occurred in four patients. One patient underwent
splenectomy during the procedure. Groin hematoma re-
quiring immediate surgical hemostasis developed in two
patients. One patient presented with thrombosis of both
limbs of the graft immediately after clamp removal. Throm-
bosis was corrected successfully by surgical thrombectomy,
and the graft remained patent during follow-up.
Complications during follow-up. Complications
were observed during the first 30 days in 107 patients
(37.0%) (Table IV). Postoperative pulmonary, urinary, and
catheter-related infection occurred in 39 patients (13.5%).
Eleven patients presented with postoperative wound infec-
tions. One patient who underwent aortofemoral bypass
presented with superficial infection during the early post-
operative period and deep infection at 2 years. There was no
early postoperative graft infection.
According to the Szilagyi classification,14 early postop-
erative wound infection was classified as grade I (superfi-
cial) in eight cases and grade II (deep) in one. Three late
femoral infections occurred after surgery, including grade
III aortobifemoral graft infections at 1 year in two cases,
with one limb of the graft involved in both cases and grade
II femoral infection at 2 years in one case.
Wound and graft infection according to the type of
bypass or indication is presented in Table V. Although
differences between groups did not reach statistical signif-
icance, a trend toward a higher incidence of wound infec-
tions was observed in the patients treated for occlusive
disease (P  .06).
Wound infection according to whether the patient
Table IV. Postoperative complications occurring during
the first 30 days in 107 patients (37%)
Complications N
Surgical 50
Lymphorrhea/lymphocele from groin incision
(not infected)
25
Infection (Szilagyi grade I or II) 9
Evisceration 6
Colon ischemia 5
Lower limb amputation with a patent
aortobifemoral graft
2
Hematoma with drainage 2
Peripheral arterial embolism 1
General 18
Transient renal insufficiency (one patient
requiring dialysis)
7
Deep venous thrombosis 6
Myocardial infarction, cardiac failure 5
Infection—nonvascular 39
Pulmonary infection 19
Urinary tract infection 17
Central line catheter with septicemia 3
Total 107underwent prior femoral surgery or presented diabetes is
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III) developed in three (16.7%) of 18 patients who had
undergone previous femoral revascularization vs eight
(3%) of 271 patients who had not undergone previous
femoral revascularization. This difference was statisti-
cally significant (P .03), with a relative risk of 5.6 (95%
CI, 1.6 to 19.5). Wound infection developed in five
(11.9%) of 42 diabetic patients vs six (2.4%) of 247
nondiabetic patients. This difference was also statistically
significant (P  .01), with a relative risk of 3.4 (95% CI,
1.7 to 6.9).
Bacteriologic tests were performed for the 12 wound
infections. Cultures were positive in all but two cases. In
one case, no bacteria were found on direct examination, but
Staphylococcus epidermidis was identified after culture. In
the other nine cases, culture was positive for S aureus in
four, including one that was methicillin-resistant, S epider-
midis and S aureus in one case, and one case each of
Escherichia coli, Proteus mirabilis, coagulase-negative
Staphylococcus, and multiresistant Serratia.
The two patients with graft infection had reoperations.
The procedure consisted of in situ replacement of the
Table V. Wound and graft infection according to type of
Aortofemoral grafts*
Grafts at risk 149
Wound infection 8 (5.4; 1.8-9.0)‡
Graft infection 2 (1.3; 0-3.2)
Occlusive disease
Grafts at risk 129
Wound infections 8 (6.2; 2.0-10.4)‡
Graft infections 2 (1.6 ; 0-3.5)
*Data in parenthesis are % and 95% confidence interval.
†Calculated by 2 test.
‡Including the two graft infections.
Table VI. Wound and graft infection according to wheth
the presence of diabetes
Pat
Wound infection according to prior femoral arterial surgery
No prior femoral surgery
Prior femoral surgery
Total
Wound infection according to diabetes status
Diabetes
No diabetes
Total
CI, Confidence interval.
*Including one graft infection.
†Including one graft infection.infected limb. The rest of the graft was left in place.DISCUSSION
This multicenter prospective study shows that the pa-
tency of the polyester bifurcated InterGard Silver graft with
a collagen and silver acetate coating was comparable with
that reported in other contemporary series describing aor-
tofemoral or aortoiliac bypass.15,16 Primary and secondary
patency were not significantly altered by risk factors or
patient age but only by underlying arterial disease. This
series confirms previous results demonstrating better pa-
tency for patients treated for aneurysm than for occlusive
disease (P  .02).17 No early graft infection occurred
despite a high rate of nosocomial infections, and only two
late graft infections (0.7%) occurred after 1 year.
Our series, with a rate of graft infection of zero in the
aortoiliac group and 1.3% in the aortofemoral group, com-
pares favorably with previously published data. We were
able to find 13 series14,18-31 with a sufficient number of
patients and adequate follow-up for each type of aortic
bypass. Table VII lists series involving aortoiliac grafts and
aortofemoral grafts. A meta-analysis of these series (Fig 6)
confirmed that the risk of graft infection was significantly
ss and indication
According to type of bypass
toiliac grafts* All grafts* P†
140 289
(2.1; 0-4.5) 11 (3.8; 1.6-6.0) .15
0 2 (0.7; 0-2.0) 0.5
According to indications
tic aneurysm All indications
160 289
(1.9; 0-4.0) 11 (3.8; 1.6-6.0) .06
0 2 (0.7; 0-2.0) 0.2
e patient underwent previous femoral arterial surgery and
(n) Infections (n) Wound infection (%) 95% CI P
8* 3.0 0.9-5.0 .03
3† 16.7 0-33.9
11 3.8 1.6-6.0
5* 11.9 2.1-21.7 0.01
6† 2.4 0.5-4.3
11 3.8 1.6-6.0bypa
Aor
3
Aor
3er th
ients
271
18
289
42
247
289lower for aortoiliac than aortofemoral grafts, with an odds
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the tendency observed in our study.
In our series, eight groin infections (5.4 %), including
two graft infections (1.3%), occurred in patients in whom
graft limb anastomosis was made on femoral arteries. In
Table VII. Graft infection in aortoiliac and aortofemoral
Authors Year
In aortoiliac grafts*
Szilagyi14 1972 
Goldstone20 1974 
Bouhoutsos21 1974 
Jamieson22 1975 
Liekweg23 1977 
Yashar24 1978 
Crawford25 1981 
Lorentzen26 1985 
O’Hara27 1986 
Szilagyi28 1986 
Edwards29 1987 
Al Khaffaf 30 1996 
This series 2006
Graft infection in aortofemoral grafts†
Szilagyi14 1972 
Goldstone20 1974 
Jamieson22 1975 
Liekweg23 1977 
Yashar24 1978 
Lorentzen26 1985 
O’Hara27 1986 
Szilagyi28 1986 
Edwards29 1987 
Al Khaffaf 30 1996 
Prager31 2003 
This series 2006
*Overall graft infection rate in these series was 0.5% (95% CI, 0.3-0.7).
†Overall graft infection rate in these series was 1.8% (95% CI, 1.5-2.1).
Fig 6. Plot comparing data concerning graft infection according
to type of bypass, ie, aortofemoral or aortoiliac (Table VII), with
calculation of odds ratio for each group. The meta-analysis dem-
onstrates a combined odds ratio of 0.28 (95% confidence interval,
0.18 to 0.42), demonstrating that graft infection rate was signifi-
cantly lower in aortoiliac grafts versus aortofemoral grafts. This
confirms the tendency observed in our study (0.21 with 95% CI,
0.01 to 4.4).addition, 25 patients (8.6%) presented with lymphocele orlymphorrhea with no infection. There was no evidence in
this study to suggest that the silver ions impair wound
healing. Although they have been under-reported in the
literature, postoperative groin wound problems are quite
common after aortofemoral bypass. In a recent case control
study on vascular graft infection from the Mayo Clinic,32
the rate of groin wound problems in the control group
without graft infection was 17.6%. Our series compares
favorably with these results. In our aortoiliac bypass group,
no patient developed graft infection, although three pa-
tients presented superficial wound infections. This finding
suggests that there is still a risk for graft infection and that
the use of the silver graft may also be useful for aortoiliac
bypass.
Analysis of our data also showed that infection occurred
significantly more often in diabetic patients and in patients
who had undergone previous revascularization procedures.
Again, this finding is consistent with the literature.33
Up until now, the main infection prevention tech-
niques at the disposal of the vascular surgeon have been
prophylactic antibiotics, strict antiseptic principles, and
sound surgical technique. By working in synergy with these
techniques, an off-the-shelf vascular graft with an antimi-
crobial protection that does not increase antibiotic resis-
tance34-36 could improve protection against infection with
no additional risk.
As stated in the introduction, it is practically impossible
s
tudy period Patients Graft infection (%)
952-1971 418 0.7
959-1973 163 1.2
957-1972 412 0.5
955-1973 325 0.9
965-1974 265 0.7
966-1977 300 1.3
955-1980 860 0.7
978-1981 425 0
959-1985 867 0.4
954-1983 76 0
975-1986 769 0
989-1991 97 0
000-2002 140 0
952-1971 1244 1.6
959-1973 260 3.0
955-1973 315 3.1
965-1974 123 5.6
966-1977 210 2.4
978-1981 1497 3.0
959-1985 2785 1.3
954-1983 1362 1.9
975-1986 1060 0.5
989-1991 102 2.9
991-1998 149 4.0
000-2002 149 1.3graft
S
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
2to quantify the impact of this strategy on graft infection
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ating sufficient statistical power.1-4 With the hypothesis of
achieving a 50% decrease in graft infection between a
control and silver graft group (from 1.4% to 0.7%), such a
study would require 3000 patients in each group. This
problem explains the disappointing results of three ran-
domized trials of antibiotic-bonded vascular grafts.37-41
Because of small size, all studies have been low powered
with a resulting potential type II statistical error. It should
be emphasized, however, that the problem of statistical
power is equally applicable to some of the most accepted
and widely practiced antiseptic techniques used in the
operating room. Although the efficacy of these techniques
has not been demonstrated by randomized clinical study,
no one would reasonably question their benefit.
This multicenter trial is subject to the same limitations.
It was neither randomized nor comparative, because such
approaches are futile owing to the statistical requirements.
Our purpose was not to prove the efficacy of the silver graft
but to evaluate complications, patency, and rates of infec-
tion, and provide further data concerning graft infections
to the medical community.
Data from various other sources have shown that the
silver-coated graft can also be useful for in situ replacement
of infected grafts.42-44 Batt et al44 addressed this issue using
silver-coated polyester grafts for in situ replacement in a
short series of 27 consecutive patients. Preliminary results
were good, but it was difficult to draw a definite conclusion
because late infections caused by organisms with low viru-
lence developed inmost of the patients. Larger series will be
necessary to compare the efficacy of the silver-coated poly-
ester grafts and other available options in an infected field.
CONCLUSIONS
Together with data being generated in vascular graft
registries, our findings improve our understanding of pros-
thetic infection and help to assess the contribution of the silver
graft to the prevention of prosthetic infection. Our results
indicate that this novel concept achieves excellent patency
with a low rate of graft infection despite a high incidence of
nosocomial infection. This suggests that increased anti-
microbial protection in the early post-operative phase could
provide long-term benefits.
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